Level C· Early human research exploring benefitsRetrospective StudyEurope PMCOpen access

Mid- and long-term functional outcomes of advancement flap for cryptoglandular perianal fistulas

van Oostendorp JY., Eddarazi A., Molenaar CBH., Zimmerman DDE., Bemelman WA., Han-Geurts IJM.

Retrospective Study with a reported sample of 35 on Autoimmune Research, published in Tech Coloproctol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Tech Coloproctol (2025)
Reported sample size
35
Source database
Europe PMC
PMID
40346397
PMCID
PMC12064625
DOI
10.1007/s10151-025-03148-w

Abstract (original English)

Background Surgical treatment for perianal fistulas requires balancing fistula closure with the risk of complications such as incontinence. The advancement flap (AF) is a widely used sphincter-sparing technique, yet it appears to offer only marginally better outcomes compared to alternative techniques, with a notable incontinence rate. This study aimed to evaluate the success rate and long-term functional outcomes of AF at our tertiary referral center. Methods This retrospective cohort study analyzed prospectively collected data from electronic medical records and questionnaires distributed in December 2023. Patients aged 18 or older with primary or recurrent perianal fistulas treated with AF between 2013 and 2023 were included. Fistulas of non-cryptoglandular origin and rectovaginal fistulas were excluded. The primary outcome was fecal incontinence. Secondary outcomes included disease burden, fistula closure, and risk factors for recurrence. Results Eighty-one patients were included; 37 (46%) were women, mean age was 45 years, and 93% had a complex fistula. The median follow-up was 27 months (IQR 15.5-64). Before AF, 36% reported some degree of incontinence, increasing to 80% at long-term follow-up after AF. Specifically, 20 out of 26 (77%) preoperative fully continent patients reported incontinence issues at long-term follow-up. Fistula disease impact on daily life was higher

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Surgical FlapsHumansRectal FistulaFecal IncontinenceRecurrencePostoperative ComplicationsTreatment OutcomeRetrospective StudiesFollow-Up StudiesTime Factors

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research